Ebola Stigma and Its Impact on Outbreak Control: Lessons From Key Informant Interviews in Central Uganda
Paterson A. et al, (2025), Tropical Medicine & International Health
Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.
Randremanana RV. et al, (2025), The New England journal of medicine, 393, 544 - 555
Mpox stigma in the UK and implications for future outbreak control: a cross-sectional mixed methods study.
Paterson A. et al, (2025), BMC Med, 23
From Reaction to Resilience: The WHO Pandemic Agreement as a Blueprint for Global Health Equity.
Hassan MZ. et al, (2025), International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 158
Vaccine effects on in-hospital COVID-19 outcomes.
Gonçalves BP. et al, (2025), Epidemiology (Cambridge, Mass.)
An hourglass model for conceptualising stigma in infectious disease outbreaks
Paterson A. et al, (2025), Scientific Reports, 15
The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study
Paterson A. et al, (2025), The Lancet Infectious Diseases
Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics
Bourner J. et al, (2025), Emerging Infectious Diseases, 31
Improving clinical care of patients in Nipah outbreaks: moving beyond 'compassionate use'.
Hassan MZ. et al, (2025), The Lancet regional health. Southeast Asia, 33
Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
Pesonel E. et al, (2025), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The priority review voucher: a misconceived quid pro quo.
Olliaro P. and Torreele E., (2024), BMJ Glob Health, 9
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa.
van Dorst PWM. et al, (2024), Applied health economics and health policy, 22, 701 - 715
Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in Burkina Faso.
Kiemde F. et al, (2024), BMC infectious diseases, 24
An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.
Randremanana RV. et al, (2024), Trials, 25
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods.
Mesinovic M. et al, (2024), Scientific reports, 14
Nipah virus disease: what can we do to improve patient care?
Hassan MZ. et al, (2024), The Lancet. Infectious diseases, 24, e463 - e471
Challenges in clinical diagnosis of Clade I Mpox: Highlighting the need for enhanced diagnostic approaches.
Bourner J. et al, (2024), PLoS neglected tropical diseases, 18
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae.
Gonçalves BP. et al, (2024), Epidemiology (Cambridge, Mass.), 35, 368 - 371
The facilitators of and barriers to antimicrobial use and misuse in Lalitpur, Nepal: a qualitative study.
Udas S. et al, (2024), BMC public health, 24